Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsEric Rose, David Stern, Ann Marie Schmidt, Talia Spanier
Estimating the term…
This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 μg/ml plasma to about 250 μg/ml plasma or from about 0.5 μg/ml plasma to about 25 μg/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The agent may be an active site-blocked Factor XII compound or an active site-blocked Factor XI compound.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is Glu-Gly-Arg chloromethyl ketone-inactivated human factor Ixa.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is a competitive inhibitor of Factor Ixa.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is a Factor IX having a Val-313 to Asp substitution in the catalytic domain thereof.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is a Factor IX having a Gly-311 to Glu substitution in the catalytic domain thereof.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is a Factor IX having a Gly-311 to Arg-318 deletion mutation.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is an a inactive Factor IXa whose amino acid sequence consists of the first 47 amino acid residues of Factor IX.
A method for inhibiting thrombosis in a patient whose blood is circulating extracorporeally which comprises introducing into the extracorporeally circulating blood a Factor IXa compound, wherein the Factor IXa compound is an anti-Factor IXa antibody.
Dependencies are inferred from the claim text.